Evidence map›Paper›PMID 37332511›Full record

ArticleFEMS microbes2022

Repurposing the PDMA-approved drugs in Japan using an insect model of staphylococcal infection.

Atsushi Miyashita, Shuhei Mitsutomi, Tohru Mizushima, Kazuhisa Sekimizu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in FEMS microbes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Cell-Free DNA-Based Theranostics for Inflammatory Disorders.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  3. Article
  4. Drug Repurposing: An Emerging Strategy inJournal of microbiology and biotechnology · 2025
    Review
  5. The Ptk2-Pma1 pathway enhances tolerance to terbinafine inAntimicrobial agents and chemotherapy · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Atsushi MiyashitaInstitute of Medical Mycology, Teikyo University, 359 Otsuka, Hachioji, Tokyo 191-0359, Japan.
Shuhei MitsutomiInstitute of Medical Mycology, Teikyo University, 359 Otsuka, Hachioji, Tokyo 191-0359, Japan.
Tohru MizushimaLTT Biopharma Co., Ltd., 1-2-20 Kaigan, Minato, Tokyo 105-0022, Japan.
Kazuhisa SekimizuSchool of Pharma-Science, Teikyo University, 359 Otsuka, Hachioji, Tokyo 191-0359, Japan.ORCID https://orcid.org/0000-0002-2849-8432

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A total of 1253 compounds approved as therapeutic drugs in Japan (Pharmaceuticals and Medical Devices Agency (PMDA)-approved compounds) were screened for their therapeutic effects against

Indexed as

drug discoverydrug repositioninginvertebrate modelsilkwormStaphylococci

Identifiers

PMID37332511
PMCPMC10117882

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.